This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Angion Biomedica Yönetim

Yönetim kriter kontrolleri 3/4

Angion Biomedica CEO'su Jay Venkatesan, May2018 tarihinde atandı, in görev süresi 5.08 yıldır. in toplam yıllık tazminatı $ 1.52M olup, şirket hissesi ve opsiyonları dahil olmak üzere 40% maaş ve 60% ikramiyelerden oluşmaktadır. şirketin hisselerinin 3.98% ine doğrudan sahiptir ve bu hisseler $ 1.20M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.5 yıl ve 4.3 yıldır.

Anahtar bilgiler

Jay Venkatesan

İcra Kurulu Başkanı

US$1.5m

Toplam tazminat

CEO maaş yüzdesi	40.0%
CEO görev süresi	5.1yrs
CEO sahipliği	4.0%
Yönetim ortalama görev süresi	3.5yrs
Yönetim Kurulu ortalama görev süresi	4.3yrs

Son yönetim güncellemeleri

Recent updates

Companies Like Angion Biomedica (NASDAQ:ANGN) Could Be Quite Risky

Apr 27

Angion Biomedica (NASDAQ:ANGN) Will Have To Spend Its Cash Wisely

Jan 05

We Think Angion Biomedica (NASDAQ:ANGN) Needs To Drive Business Growth Carefully

Sep 11

Angion Biomedica Corp.'s (NASDAQ:ANGN) Intrinsic Value Is Potentially 49% Above Its Share Price

Oct 05

We're Hopeful That Angion Biomedica (NASDAQ:ANGN) Will Use Its Cash Wisely

Aug 18

CEO Tazminat Analizi

Jay Venkatesan'un ücretlendirmesi Angion Biomedica'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2023	n/a	n/a	-US$29m
Dec 31 2022	US$2m	US$608k	-US$39m
Sep 30 2022	n/a	n/a	-US$17m
Jun 30 2022	n/a	n/a	-US$24m
Mar 31 2022	n/a	n/a	-US$32m
Dec 31 2021	US$3m	US$587k	-US$55m
Sep 30 2021	n/a	n/a	-US$98m
Jun 30 2021	n/a	n/a	-US$100m
Mar 31 2021	n/a	n/a	-US$104m
Dec 31 2020	US$1m	US$570k	-US$80m
Sep 30 2020	n/a	n/a	-US$67m
Dec 31 2019	US$2m	US$473k	-US$41m

Tazminat ve Piyasa: Jay 'nin toplam tazminatı ($USD 1.52M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 647.72K ).

Tazminat ve Kazançlar: Jay 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Jay Venkatesan (51 yo)

5.1yrs

Görev süresi

US$1,518,849

Tazminat

Dr. Jay R. Venkatesan, Ph D., M.D. MBA., serves as Chairman of Angion Biomedica Corp. since January 2022 and also serves as its President since January 2019 and has been its Chief Executive Officer & Direc...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jay Venkatesan	President	5.1yrs	US$1.52m	3.98% $ 1.2m
Jennifer Rhodes	Executive VP	3.4yrs	US$773.65k	0.048% $ 14.6k
Gregory Curhan	Chief Financial Officer	3yrs	US$1.38m	0.013% $ 4.0k
Daniel Iazzetti	Vice President of Human Resources	3.7yrs	Veri yok	Veri yok

3.5yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: ANGN 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jay Venkatesan	President	5.1yrs	US$1.52m	3.98% $ 1.2m
Victor Ganzi	Lead Independent Non-Employee Director	5.2yrs	US$93.78k	3.25% $ 978.7k
Gilbert Omenn	Independent Non-Employee Director	3.4yrs	US$76.78k	0.27% $ 80.3k
Karen Wilson	Independent Non-Employee Director	3.2yrs	US$81.28k	0.062% $ 18.7k
Joseph Bonventre	Chairperson of Scientific Advisory Board	no data	Veri yok	Veri yok
Allen Nissenson	Independent Non-Employee Director	3.4yrs	US$78.78k	0.031% $ 9.4k
Anupam Agarwal	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Itzhak Goldberg	Chairman Emeritus	25.2yrs	US$854.33k	5.61% $ 1.7m
Matthew Cooper	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Matthew Weir	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Michael Koren	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Sumit Mohan	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

74yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ANGN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).

This company is no longer active

Angion Biomedica Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

Angion Biomedica Corp. Announces Resignation of John F. Neylan as Chief Medical Officer and Head of Research, Effective on August 15, 2022

President recently bought US$101k worth of stock

Interim Chief Financial Officer notifies of intention to sell stock

President recently bought US$730k worth of stock

President recently bought US$106k worth of stock

Recent updates

Elicio Therapeutics, Inc. completed the acquisition of Angion Biomedica Corp. (NasdaqGS:ANGN) from Vifor (International) AG, Eisa-Abc LLC and others in a reverse merger transaction.

First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.47 loss in 1Q 2022)

Insufficient new directors

Companies Like Angion Biomedica (NASDAQ:ANGN) Could Be Quite Risky

Full year 2022 earnings released: US$1.29 loss per share (vs US$1.93 loss in FY 2021)

Elicio Therapeutics, Inc. entered into a definitive merger agreement to acquire Angion Biomedica Corp. (NasdaqGS:ANGN) in a reverse merger transaction.

Angion Biomedica (NASDAQ:ANGN) Will Have To Spend Its Cash Wisely

Angion Biomedica Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

Price target decreased to US$1.50

We Think Angion Biomedica (NASDAQ:ANGN) Needs To Drive Business Growth Carefully

Second quarter 2022 earnings released: US$0.30 loss per share (vs US$0.57 loss in 2Q 2021)

Angion Biomedica GAAP EPS of -$0.30, revenue of $0.7M misses by $0.08M

Angion Biomedica Corp. Announces Resignation of John F. Neylan as Chief Medical Officer and Head of Research, Effective on August 15, 2022

Price target increased to US$14.75

Angion Biomedica Corp. Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney Disease

Angion to discontinue phase 2 trial of ANG-3070 in patients with kidney disease

President recently bought US$101k worth of stock

First quarter 2022 earnings released: US$0.47 loss per share (vs US$1.57 loss in 1Q 2021)

Angion Announces Phase 1b Trial of ANG-3070 in Patients with Idiopathic Pulmonary Fibrosis

Price target decreased to US$15.00

Full year 2021 earnings released: US$1.93 loss per share (vs US$5.43 loss in FY 2020)

We Think Angion Biomedica (NASDAQ:ANGN) Can Afford To Drive Business Growth

Angion Biomedica: Selling At Cash Value

Interim Chief Financial Officer notifies of intention to sell stock

Angion Biomedica Corp. Provides ANG-3070 Program Update

President recently bought US$730k worth of stock

President recently bought US$106k worth of stock

Angion Biomedica Corp. and Vifor Pharma AG Report Topline Results from Phase 2 Guard Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injury

Key Executive notifies of intention to sell stock

Key Executive notifies of intention to sell stock

Angion Biomedica Corp.'s (NASDAQ:ANGN) Intrinsic Value Is Potentially 49% Above Its Share Price

We're Hopeful That Angion Biomedica (NASDAQ:ANGN) Will Use Its Cash Wisely

Angion Biomedica Corp Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021

Angion Biomedica Corp. Announces Results from the Phase 2 ALI-201 Study in Patients with COVID-19 Associated Pneumonia

Angion Biomedica Corp.(NasdaqGS:ANGN) dropped from Russell Microcap Value Index

Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury

Angion Biomedica Corp. announced that it has received $25 million in funding from Vifor (International) AG

Angion Biomedica Corp. has completed an IPO in the amount of $80 million.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş